Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Q1 2026 Coheris Oncology Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1, 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead. Thank you, Heidi. Good afternoon, and welcome to Coherent Oncology's first quarter 2026 earnings conference call. Joining me today to discuss our results are Denny Lancer, Chief Executive Officer of Coherent, Dr. Rosh Dias, Chief Medical Officer, Dr. Theresa Lavallee, Chief Scientific and Development Officer, Samira Ghori-Gokhar, Chief Commercial Officer, and Brian McMichael, Chief Financial Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding COHER's current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly report on form 10Q for more information on risks and uncertainties. And now I'll turn the call over to Denny. Well, thank you, Carrie. And thank you all for joining us this afternoon on our Q1 2026 quarterly call. Let me first give you a quick flyby of the company's strategy to make sure we level set everyone, including our new investors. That strategy starts with Bactorsi, our next generation differentiated PD-1 i...